Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Phase 2

Recruiting

• Conditions: Pancreatic Cancer Resectable
• Interventions: Drug: Nimotuzumab; Drug: AG

• Registration Number: NCT06722911
• Lead Sponsor: Zhejiang Provincial People's Hospital

Brief Summary

This is a prospective, single-arm trial. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with nab-paclitaxel+ gemcitabine (AG regimen) for postoperative adjuvant treatment of pancreatic cancer with EGFR-positive.

Detailed Description

This clinical study is designed as a prospective, open-label, single arm, phase II study to evaluate the clinical efficacy and safety of Nimotuzumab combined with AG (nab-paclitaxel+ gemcitabine) as postoperative adjuvant therapy in patients with EGFR-positive pancreatic cancer. The main endpoint is disease-free survival (DFS). Additional end points included...

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2024-11-15
• Status Verified: 2024-12
• Study First Submitted: 2024-12-04
• Study First Submitted QC: 2024-12-04
• Last Update Submitted: 2024-12-04
• Study First Posted: 2024-12-09
• Last Update Posted: 2024-12-09
• Primary Completion: 2028-09-30
• Study Completion: 2028-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• 1. Able and willing to provide a written informed consent.
• 2. Age 18-75 years old, gender unlimited;
• 3. Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;
• 4. Postoperative pathology suggested R0/R1 resection;
• 5. EGFR positive (by immunohistochemistry);
• 6. KRAS gene and CDX-2 protein status must have been determined at baseline (only for post hoc analysis);
• 7. Adequate organ and bone marrow function, defined as follows: absolute neutrophil count (ANC)≥1.5×10^9/L; platelets≥80×10^9/L; hemoglobin≥9.0 g/dL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance > 60 mL/min;
• 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• 9. Postoperative survival is expected to be ≥3 months;
• 10. Fertile subjects are willing to take contraceptive measures during the study period.

Read More

Exclusion Criteria

• 1. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;
• 2. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
• 3. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP>160mmHg or DBP>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;
• 4. Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;
• 5. CA199>180 U/ml within 21d before adjuvant therapy;
• 6. Known allergy to prescription or any component of the prescription used in this study;
• 7. Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);
• 8 .Other reasons that are not suitable to participate in this study according to the researcher's judgment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Nimotuzumab+ AG	Nimotuzumab	-
Nimotuzumab+ AG	AG	-

Primary Outcome Measures

Name	Time	Method
disease-free survival (DFS)	Up to 24 months	The time from the date of surgery to the disease recurrence or death, whichever is earlier.

Secondary Outcome Measures

Name	Time	Method
distant metastasis-free survival (DMFS)	Up to 24 months	The time from the date of surgery to the first distant metastasis or death due to any cause, whichever is earlier.
overall survival (OS)	Up to 24 months	The time from the date of surgery to death due to any cause.
tumor-related markers	Up to 24 months	To explore the influence of tumor-related markers (such as KRAS gene, CDX-2 protein, etc.) on prognosis.
adverse events	Up to 30 days after last administration	Frequency and severity of adverse events.

Trial Locations

Locations (1)

Zhejiang Provincial People's Hospital; 🇨🇳 Hangzhou, Zhejiang, China